With a clinical trial and 'plug-and-play' tech, Rochester's Vyriad wants to advance blood cancer care

With a clinical trial and 'plug-and-play' tech, Rochester's Vyriad wants to advance blood cancer care

ROCHESTER — Later this year, a Rochester biotechnology company anticipates treating its first patient with a novel form of CAR-T therapy that takes place within the body itself. "This is very, very early days of this kind of technology being tested in human patients," said Luke Russell, executive vice president of Vyriad. Chimeric antigen receptor T-cell, or CAR-T, therapies use viral vectors — shells of viruses without the ability to replicate …